Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Legend Biotech Corp ADR
(NQ:
LEGN
)
57.06
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Legend Biotech Corp ADR
< Previous
1
2
3
4
Next >
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
June 01, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2022
From
Legend Biotech
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 26, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
May 18, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
May 09, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
May 06, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Appointment of Global Head of Research and Early Development
April 01, 2022
From
Legend Biotech Corporation
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
March 25, 2022
From
Legend Biotech
Via
Business Wire
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
March 23, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 18, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
February 18, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
February 15, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
February 11, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
December 30, 2021
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Corporation Announces Pricing of Public Offering
December 16, 2021
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Corporation Announces Proposed Public Offering
December 14, 2021
From
Legend Biotech Corporation
Via
Business Wire
Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma
December 13, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
December 07, 2021
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting
December 07, 2021
From
Legend Biotech
Via
Business Wire
KILL Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
December 06, 2021
Via
Business Wire
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
December 06, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights
November 16, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH
November 04, 2021
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel
November 01, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech to Host R&D Day on October 18, 2021
September 22, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
September 13, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
August 30, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights
August 23, 2021
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Advancement of Global Manufacturing Infrastructure
June 22, 2021
From
Legend Biotech
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.